Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

The US government has a further option for the supply of another 500 million doses in the longer term. Sanofi is leading the clinical development and registration of the COVID-19 vaccine and ...

with twice-weekly dosing by intravenous infusion after a titration period of two once-weekly doses, based on the patient's body weight. Sanofi estimates that the annual cost for a typical patient ...

The approval is for both a 3 milliliter single-patient-use prefilled pen and a 10 milliliter multiple-dose vial ... FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human immunoglobulin G 1(IgG1)-λ2 monoclonal antibody, duvakitug, in treating moderate-to ...